KR20060015296A - 신경교 기원의 종양의 진단 및 치료를 위한 조성물 및 방법 - Google Patents

신경교 기원의 종양의 진단 및 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20060015296A
KR20060015296A KR1020057022428A KR20057022428A KR20060015296A KR 20060015296 A KR20060015296 A KR 20060015296A KR 1020057022428 A KR1020057022428 A KR 1020057022428A KR 20057022428 A KR20057022428 A KR 20057022428A KR 20060015296 A KR20060015296 A KR 20060015296A
Authority
KR
South Korea
Prior art keywords
antibody
seq
polypeptide
tat
oligopeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057022428A
Other languages
English (en)
Korean (ko)
Inventor
하이디 필립스
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20060015296A publication Critical patent/KR20060015296A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020057022428A 2003-05-23 2004-05-21 신경교 기원의 종양의 진단 및 치료를 위한 조성물 및 방법 Withdrawn KR20060015296A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47323803P 2003-05-23 2003-05-23
US60/473,238 2003-05-23
US54829904P 2004-02-27 2004-02-27
US60/548,299 2004-02-27

Publications (1)

Publication Number Publication Date
KR20060015296A true KR20060015296A (ko) 2006-02-16

Family

ID=33544287

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057022428A Withdrawn KR20060015296A (ko) 2003-05-23 2004-05-21 신경교 기원의 종양의 진단 및 치료를 위한 조성물 및 방법

Country Status (9)

Country Link
US (2) US20050112129A1 (https=)
EP (1) EP1628679A2 (https=)
JP (1) JP4703567B2 (https=)
KR (1) KR20060015296A (https=)
AU (1) AU2004249125A1 (https=)
CA (1) CA2524567A1 (https=)
MX (1) MXPA05012613A (https=)
NZ (1) NZ543751A (https=)
WO (1) WO2004112829A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AU2002367318B2 (en) * 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004106495A2 (en) 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7473531B1 (en) * 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US7824685B2 (en) * 2004-01-26 2010-11-02 Baylor College Of Medicine RTVP based compositions and methods for the treatment of prostate cancer
JP4840866B2 (ja) * 2005-01-19 2011-12-21 学校法人慶應義塾 癌ワクチン
ATE501276T1 (de) * 2005-07-26 2011-03-15 Council Scient Ind Res Verfahren zur gliomdiagnose mit unterscheidung zwischen progressiven und de-novo-formen
ES2330904B1 (es) * 2005-09-21 2010-09-23 Fundacio Centre De Recerca En Sanitat Animal Polinucleotidos de haemophilus parasuis y su uso.
WO2007059170A2 (en) * 2005-11-15 2007-05-24 University Of South Florida Detection of pkc-iota as a biomarker for brain tumorigenesis
CA2643737C (en) 2006-03-13 2020-05-05 Mubio Products Bv Cancer vaccine
EP2091565A2 (en) * 2006-11-29 2009-08-26 Genentech, Inc. Method of diagnosing and treating glioma
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
EP2545938A1 (en) 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutic use of anti-tweak receptor antibodies
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
BRPI0906261A2 (pt) * 2008-03-31 2015-07-07 Genentech Inc "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
EP2216399A1 (en) * 2009-01-30 2010-08-11 Université de la Méditerranée Human soluble CD146, preparation and uses thereof
SG178845A1 (en) 2009-08-21 2012-04-27 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
WO2011022709A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vitro screening assays
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
SG185027A1 (en) * 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
CN103491978A (zh) * 2010-10-25 2014-01-01 明尼苏达大学评议会 用于治疗成胶质细胞瘤的治疗组合物
RU2578468C2 (ru) 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CA3012006A1 (en) * 2017-07-31 2019-01-31 Modern Meadow, Inc. Yeast strains and methods for controlling hydroxylation of recombinant collagen
WO2024107709A2 (en) * 2022-11-14 2024-05-23 Board Of Regents, The University Of Texas System Compositions and methods of using nitration resistant ccl2 chemokines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6518061B1 (en) * 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US6150162A (en) 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US6960651B2 (en) * 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
WO2001036685A2 (en) 1999-11-17 2001-05-25 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
DE60238143D1 (de) * 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren

Also Published As

Publication number Publication date
US8008004B2 (en) 2011-08-30
EP1628679A2 (en) 2006-03-01
US20070231323A1 (en) 2007-10-04
MXPA05012613A (es) 2006-05-25
CA2524567A1 (en) 2004-12-29
AU2004249125A1 (en) 2004-12-29
NZ543751A (en) 2008-05-30
US20050112129A1 (en) 2005-05-26
WO2004112829A2 (en) 2004-12-29
WO2004112829A3 (en) 2005-03-31
JP4703567B2 (ja) 2011-06-15
JP2007516232A (ja) 2007-06-21

Similar Documents

Publication Publication Date Title
KR100607612B1 (ko) 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
AU2022201153B2 (en) Methods and compositions for detecting esophageal neoplasias and/or metaplasias in the esophagus
KR20060015296A (ko) 신경교 기원의 종양의 진단 및 치료를 위한 조성물 및 방법
AU2023251441A1 (en) RNA containing composition for treatment of tumor diseases
AU2017235661B2 (en) Oligonucleotide probes and uses thereof
KR20050048615A (ko) 종양의 진단 및 치료를 위한 조성물 및 방법
AU2017267184B2 (en) Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy
KR101234281B1 (ko) 염색체 안정화에 관한 유전자를 표적으로 하는 암세포 특이적 아포토시스 유도제
KR20070100235A (ko) 종양의 진단 및 치료를 위한 조성물 및 방법
US11103538B2 (en) Targeting epigenetic regulators using a bacterial delivery system
US6262333B1 (en) Human genes and gene expression products
TW202321448A (zh) 利用重組環狀rna改善蛋白質轉譯的組合物及方法
KR20120082906A (ko) 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
KR20060055559A (ko) 종양의 진단 및 치료 방법 및 이를 위한 조성물
KR20150129847A (ko) 융합 단백질 및 이들의 방법
JP2003135075A (ja) 新規な全長ｃＤＮＡ
JP2003088388A (ja) 新規な全長ｃＤＮＡ
EP1165784A2 (en) Nucleic acids including open reading frames encoding polypeptides; "orfx"
KR20180020125A (ko) 변형된 t 세포 및 이의 제조 및 사용 방법
KR20220054401A (ko) 감염의 숙주 rna 바이오마커의 신속한 조기-검출 및 인간의 covid-19 코로나바이러스 감염의 조기 식별을 위한 시스템, 방법 및 조성물
JP2003304888A (ja) 化合物の毒性予測のための方法
KR20190120170A (ko) Vhh-함유 중쇄 항체 및 이의 생산
KR20040065524A (ko) 백혈병을 검사 및 치료하는 방법
KR20190104400A (ko) 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
US20020137077A1 (en) Genes regulated in activated T cells

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000